The European launch of the ACIST Pro™ Diagnostic System marks a significant advancement in contrast management technologies for hospital cardiology departments across Europe. Developed by ACIST Medical Systems, a Bracco Group company, this next-generation variable-rate contrast management solution is designed to improve precision, safety, and efficiency during image-guided cardiovascular procedures. Hospitals in selected European markets can now access this innovative technology, which builds upon the established ACIST CVi® system, addressing the evolving needs of interventional cardiology teams.

Dr. Fulvio Renoldi Bracco, CEO of Bracco Imaging, emphasized the importance of this launch, stating that it represents an ongoing commitment to advancing precision imaging across medical specialties. The system responds to real-world demands in cardiac catheterization laboratories by enhancing workflow efficiency and supporting sustainability goals in diagnostic imaging. This development is particularly relevant for **Healthcare Management** and **Cardiology** professionals managing high-volume procedural environments where contrast optimization is critical to patient outcomes and operational costs.

The ACIST Pro™ features advanced capabilities for variable-rate contrast delivery, enabling clinicians to tailor injections more precisely to patient anatomy and procedural requirements. This reduces contrast volume usage, minimizing risks such as contrast-induced nephropathy while maintaining high-quality imaging for diagnostics and interventions. For hospital administrators and procurement teams, the system's integration with existing cath lab infrastructures offers a seamless upgrade path, potentially lowering long-term consumable costs and improving throughput in busy facilities.

In the context of Europe's healthcare landscape, where cardiovascular diseases remain a leading cause of mortality, innovations like the ACIST Pro™ align with strategic priorities for digital transformation and technology deployment in **Diagnostics and Imaging**. Bracco Group's investment in R&D, amounting to approximately 9% of its turnover, underscores its leadership in medical devices, with over 2,000 active patents supporting a portfolio that spans more than 100 countries. This launch extends the company's footprint in interventional cardiology, radiology, and vascular care, providing hospitals with tools to enhance procedural safety and performance.

Brad Fox, CEO of ACIST Medical Systems, highlighted the evolution from the trusted ACIST CVi® platform, noting improved performance metrics that benefit clinical teams daily. The technology's European rollout follows its introduction in Japan in 2025, with further global expansion planned throughout 2026. Pending FDA clearance in the United States signals broader international adoption, but the immediate availability in Europe positions adopting hospitals at the forefront of contrast management innovation.

For **Facilities Management** and clinical leadership, the ACIST Pro™ supports sustainability initiatives by optimizing contrast media usage, reducing waste, and aligning with regulatory pressures for greener healthcare practices. Its design facilitates easier maintenance and integration, crucial for resource-constrained environments. Procurement professionals will appreciate the system's potential to streamline supply chains for contrast agents, a persistent challenge amid ongoing shortages in pharmaceutical supplies.

Bracco Group's robust infrastructure, including facilities in key regions, ensures reliable support and service for European customers. With over 3,800 employees and €2 billion in annual revenues—88% from international markets—the company is well-positioned to scale this technology across hospital networks. ACIST's global presence, with operations in the USA, Silicon Valley, Heerlen, and Tokyo, further bolsters deployment and training capabilities for end-users.

This launch comes at a pivotal time for European hospitals navigating post-pandemic recovery, workforce challenges, and the push for interoperable technologies. By enhancing cath lab efficiency, the ACIST Pro™ contributes to better patient monitoring and emergency care in cardiology settings, fitting squarely within **Patient Monitoring Emergency Care** and **Critical Care** categories. Hospitals adopting this system can expect measurable improvements in procedural times, radiation dose reduction, and overall patient safety metrics.

Looking ahead, the collaboration between Bracco and ACIST exemplifies strategic partnerships driving medtech innovation. For decision-makers in **Healthcare Information Technology** and equipment procurement, evaluating the ACIST Pro™ offers an opportunity to future-proof cardiology suites against emerging demands like complex structural heart interventions and high-risk patient cohorts. Detailed specifications and clinical data are available through manufacturer channels, enabling informed investment decisions aligned with organizational goals.

In summary, the European launch empowers hospital teams with cutting-edge tools to elevate standards in cardiovascular care, reinforcing Bracco's role as a global leader in diagnostic imaging solutions. This development promises lasting impacts on operational excellence and clinical excellence across the continent.